NOT FOR DISTRIBUTION
Header cover image

Market Cap

€567.4m

Last Updated

2021/04/14 18:31 UTC

Data Sources

Company Financials +

Executive Summary

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. More Details


Snowflake Analysis

Very undervalued with excellent balance sheet.


Similar Companies

Share Price & News

How has Antares Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MJC is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: MJC's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-1.7%

MJC

2.9%

DE Medical Equipment

0.2%

DE Market


1 Year Return

43.1%

MJC

41.5%

DE Medical Equipment

42.4%

DE Market

Return vs Industry: MJC exceeded the German Medical Equipment industry which returned 41.5% over the past year.

Return vs Market: MJC matched the German Market which returned 42.4% over the past year.


Shareholder returns

MJCIndustryMarket
7 Day-1.7%2.9%0.2%
30 Day-8.3%7.6%5.1%
90 Day0.6%13.0%9.6%
1 Year43.1%43.1%43.2%41.5%47.0%42.4%
3 Year75.3%75.3%95.4%87.0%23.5%12.8%
5 Year345.6%345.6%338.7%322.5%51.0%29.5%

Long-Term Price Volatility Vs. Market

How volatile is Antares Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Antares Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MJC (€3.4) is trading below our estimate of fair value (€12.59)

Significantly Below Fair Value: MJC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MJC is good value based on its PE Ratio (11.9x) compared to the DE Medical Equipment industry average (46.3x).

PE vs Market: MJC is good value based on its PE Ratio (11.9x) compared to the German market (28.2x).


Price to Earnings Growth Ratio

PEG Ratio: MJC is good value based on its PEG Ratio (1x)


Price to Book Ratio

PB vs Industry: MJC is good value based on its PB Ratio (5.7x) compared to the DE Medical Equipment industry average (7.9x).


Future Growth

How is Antares Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

12.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MJC's forecast earnings growth (12.3% per year) is above the savings rate (0.07%).

Earnings vs Market: MJC's earnings (12.3% per year) are forecast to grow slower than the German market (20.9% per year).

High Growth Earnings: MJC's earnings are forecast to grow, but not significantly.

Revenue vs Market: MJC's revenue (14.6% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: MJC's revenue (14.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MJC's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Antares Pharma performed over the past 5 years?

59.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MJC has a high level of non-cash earnings.

Growing Profit Margin: MJC became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: MJC has become profitable over the past 5 years, growing earnings by 59.6% per year.

Accelerating Growth: MJC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MJC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (44.3%).


Return on Equity

High ROE: MJC's Return on Equity (47.2%) is considered outstanding.


Financial Health

How is Antares Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: MJC's short term assets ($126.6M) exceed its short term liabilities ($63.2M).

Long Term Liabilities: MJC's short term assets ($126.6M) exceed its long term liabilities ($30.2M).


Debt to Equity History and Analysis

Debt Level: MJC's debt to equity ratio (34.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MJC's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: MJC's debt is well covered by operating cash flow (52.1%).

Interest Coverage: MJC's interest payments on its debt are well covered by EBIT (3.6x coverage).


Balance Sheet


Dividend

What is Antares Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MJC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MJC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MJC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MJC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MJC's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Bob Apple (54 yo)

5.25yrs

Tenure

US$3,514,955

Compensation

Mr. Robert F. Apple, also known as Bob, has been the Chief Executive Officer and President of Antares Pharma Inc. since January 25, 2016. Mr. Apple served as Chief Operating Officer of Antares Pharma Inc. ...


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD3.51M) is above average for companies of similar size in the German market ($USD1.15M).

Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MJC's management team is considered experienced (4.5 years average tenure).


Board Members

Experienced Board: MJC's board of directors are considered experienced (7.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Antares Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Antares Pharma, Inc.
  • Ticker: MJC
  • Exchange: DB
  • Founded: 1978
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$679.371m
  • Listing Market Cap: US$567.411m
  • Shares outstanding: 168.16m
  • Website: https://www.antarespharma.com

Number of Employees


Location

  • Antares Pharma, Inc.
  • 100 Princeton South
  • Suite 300
  • Ewing
  • New Jersey
  • 8628
  • United States

Listings


Biography

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therape...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/14 18:31
End of Day Share Price2021/04/13 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.